There are 2,600 gen and cell therapy clinical trials taking place this year. In the US alone, this could translate up to 20 new therapy approvals in 2022, which presents a clear opportunity to make more life-saving therapies available to a greater number of individuals. As the evolution of medicine continues, the future looks promising for advancements in cell and gene therapy.

In this podcast, Adlai Goldberg, Global Digital, Social and Commercial Innovation Life Sciences Leader for EY, talks to Tamie Joeckel – ICON’s Cell and Gene Therapy Global Business Lead, as they discuss the use of technology in medicine and what makes an increase in the volume of clinical trials, including cgt clinical trials, and an acceleration of the clinical trial process significant.